320 BASELINE AND SUPEROVULATION HYPERANDROGENISM AND FOLLICULAR DYNAMICS IN THE OSSABAW PIG SUGGEST AN ANIMAL MODEL FOR POLYCYSTIC OVARY SYNDROME

2011 ◽  
Vol 23 (1) ◽  
pp. 256 ◽  
Author(s):  
A. E. Newell-Fugate ◽  
J. N. Taibl ◽  
S. G. Clark ◽  
M. Alloosh ◽  
M. Sturek ◽  
...  

The objective of this study was to validate the obese Ossabaw pig as a model of the obese polycystic ovary syndrome (PCOS) phenotype. Four sows were fed a high fat–high fructose diet to induce metabolic syndrome (MetS), and 5 sows were fed a control diet (Lean). Sows had twice-weekly blood collection and ovarian ultrasound; serum was assessed weekly for androstenedione (A) and twice weekly for progesterone (P). The follicular phase of the oestrous cycle was determined by absence of a corpus luteum on ultrasound and a nadir in P below 2.5 ng mL–1. After baseline measurement collection, sows were down-regulated with a GnRH agonist and superovulated with subcutaneous FSH/LH injections administered every 8 h until large follicles (5–12.5 mm) were visible on the ultrasound (3–7 days), at which point hCG was administered. Oestrous cycle data were divided into follicular (F), early luteal (EL), mid-luteal (ML), late luteal (LL), and transition (T) phases. Superovulation data were subdivided by percentage of stimulation completion and number of days post-hCG. Non-normal data were transformed before analysis with PROC MIXED for repeated-measures in SAS. The MetS sows had a longer average oestrous cycle length than did Lean sows (MetS, 32.2 ± 1.3 days; Lean, 25.2 ± 1.0 days; P < 0.05). In each cycle phase, with the exception of T, MetS A (F: 1.95 ± 0.01 ng mL–1, EL: 1.31 ± 0.07 ng mL–1, ML: 1.14 ± 0.04 ng mL–1, LL: 1.34 ± 0.04 ng mL–1) was higher (P < 0.05) than Lean A (F: 1.11 ± 0.09 ng mL–1, EL: 0.98 ± 0.07 ng mL–1, ML: 0.98 ± 0.04 ng mL–1, LL: 1.04 ± 0.04 ng mL–1). Within the MetS sows, A was significantly higher in F compared with the entire luteal (L) phase (1.25 ± 0.05 ng mL–1; P < 0.05). The MetS sows had similar numbers of large follicles in the F (3.0 ± 1.1 avg pig–1) and L (3.6 ± 1.1 avg pig–1) phases, whereas Lean sows had fewer large follicles during L (0.7 ± 1.1 avg pig–1) compared with F (3.0 ± 1.1 avg pig–1) phase (P < 0.05). The MetS sows had more large follicles than did Lean sows during the EL (MetS, 7.0 ± 1.1, Lean, 0.0 ± 0.0; P < 0.05) and T phases (MetS, 4.0 ± 1.1; Lean, 1.0 ± 1.1; P < 0.05). Lean sows did not form any cystic structures (CS; >12.5 mm). The MetS sows had significantly more CS than did Lean sows during the EL and ML phases (2.0 ± 0.5 avg pig–1; P < 0.05). In response to superovulation, MetS sows had higher A than did Lean sows at completion of stimulation (MetS, 8.45 ± 1.75 ng mL–1; Lean, 2.79 ± 1.36 ng mL–1; P < 0.05) and tended to have higher A than did Lean sows one day post-hCG administration (MetS, 6.00 ± 1.75 ng mL–1; Lean, 2.53 ± 1.36 ng mL–1; P = 0.09). Although not significantly different, MetS sows produced higher numbers of large follicles (range: 9.0–58.6 avg pig–1) than did Lean sows (range: 6.3–33.3 avg pig–1). In conclusion, MetS sows have long oestrous cycles, are hyperandrogenemic, have increased numbers of large follicles in the luteal phase, form cystic structures, and may recruit abnormally high numbers of large follicles in response to superovulation. The obese Ossabaw sow is an excellent animal model in which to study PCOS because women with this disease similarly have oligomenorrhea, hyperandrogenism and ovarian cysts, and recruit high numbers of large follicles at superovulation.

Author(s):  
Ana Lúcia de Oliveira Bonfá ◽  
Eduardo Donato Alves ◽  
Víctor Fabrício ◽  
Keico Okino Nonaka ◽  
Janete Aparecida Anselmo-Franci ◽  
...  

Polycystic ovary syndrome (PCOS) is one of the most widely recognized endocrine disorders affecting reproductive-age women. The etiopathogenesis and mechanisms of this syndrome remain unclear. Diagnosis requires two of the following: polycystic ovaries, oligo- or anovulation, and hyperandrogenism. Most women with PCOS display conditions such as metabolic abnormalities, diabetes, obesity, cardiovascular disease, and/or bone dysfunction. Considering the ethical limitations of human studies, animal and cell culture models that reflect some features of PCOS are important for investigation of this syndrome. The aim of the present work was to study some of the endocrine relationships between ovaries and bone tissue in a polycystic ovary syndrome animal model. The study was performed using an estradiol valerate PCOS-induced rat model (n = 30) and bone mesenchymal stem cell cultured from bone marrow of those animals. It was hypothesized that changes of the endocrine relationship between ovaries and bones could be observed in from in vivo animal model and in vitro cell culture assays. The ovarian morphological and endocrine changes seem to be correlated with endocrine, biophysical, and biomechanical changes in bone properties. Mesenchymal stem cells obtained from PCOS-induced rats, cultured for up to 21 days and differentiated into osteoblasts, presented lower viability and reduced mineralization of the extracellular matrix. Taken together, these results indicate important endocrine and structural effects of PCOS in ovaries and bones, contributing to part of the understanding of the pathophysiological mechanisms of PCOS.


2017 ◽  
Vol 125 (08) ◽  
pp. 522-529 ◽  
Author(s):  
Danijela Milutinović ◽  
Marina Nikolić ◽  
Nataša Veličković ◽  
Ana Djordjevic ◽  
Biljana Bursać ◽  
...  

AbstractPolycystic ovary syndrome is a heterogeneous endocrine and metabolic disorder associated with abdominal obesity, dyslipidemia and insulin resistance. Since abdominal obesity is characterized by low-grade inflammation, the aim of the study was to investigate whether visceral adipose tissue inflammation linked to abdominal obesity and dyslipidemia could lead to impaired insulin sensitivity in the animal model of polycystic ovary syndrome.Female Wistar rats were treated with nonaromatizable 5α-dihydrotestosterone pellets in order to induce reproductive and metabolic characteristics of polycystic ovary syndrome. Glucose, triglycerides, non-esterified fatty acids and insulin were determined in blood plasma. Visceral adipose tissue inflammation was evaluated by the nuclear factor kappa B intracellular distribution, macrophage migration inhibitory factor protein level, as well as TNFα, IL6 and IL1β mRNA levels. Insulin sensitivity was assessed by intraperitoneal glucose tolerance test and homeostasis model assessment index, and through analysis of insulin signaling pathway in the visceral adipose tissue.Dihydrotestosterone treatment led to increased body weight, abdominal obesity and elevated triglycerides and non-esterified fatty acids, which were accompanied by the activation of nuclear factor kappa B and increase in macrophage migration inhibitory factor, IL6 and IL1β levels in the visceral adipose tissue. In parallel, insulin sensitivity was affected in 5α-dihydrotestosterone-treated animals only at the systemic and not at the level of visceral adipose tissue.The results showed that abdominal obesity and dyslipidemia in the animal model of polycystic ovary syndrome were accompanied with low-grade inflammation in the visceral adipose tissue. However, these metabolic disturbances did not result in decreased tissue insulin sensitivity.


Medicina ◽  
2021 ◽  
Vol 57 (10) ◽  
pp. 1024
Author(s):  
Sonia Shirin ◽  
Faye Murray ◽  
Azita Goshtasebi ◽  
Dharani Kalidasan ◽  
Jerilynn C. Prior

Background and Objectives: Women with androgenic Polycystic Ovary Syndrome (PCOS) have increased endometrial cancer risk that cyclic progesterone will prevent; it may also reverse PCOS’s neuroendocrine origins. This pilot study’s purpose was to document 6-month experience changes in a woman with PCOS taking cyclic progesterone therapy because she was intolerant of combined hormonal contraceptive therapy, the current PCOS standard of care. A 31-year-old normal-weight woman with PCOS had heavy flow, irregular cycles, and was combined hormonal contraceptives-intolerant. She was prescribed cyclic oral micronized progesterone (OMP) (300 mg/h.s. cycle days 14–27). She kept Menstrual Cycle Diary© (Diary) records, starting with the 1st treatment cycle for six cycles; she was on no other therapy. Statistical analysis a priori hypothesized progesterone decreases high estradiol (E2) experiences (flow, cervical mucus, fluid retention, front-of-the-breast tenderness and anxiety); analysis focused on these. Our objectives: (1) changes from cycles 1 to 6 in E2-related experiences; and (2) follicular phase E2-related changes from cycle 1 (no therapy) to cycles 3 and 6. Materials and Methods: Data from consecutive Diaries were entered into an SPSS database and analyzed by Wilcoxon Signed Rank Test (Objective #1) within-person whole cycle ordinal data, and (Objective #2 follicular phase) repeated measures ANOVA. Results: Cyclic OMP was associated with regular, shorter cycles (±SD) (28.2 ± 0.8 days). Comparison of cycles 1–6 showed decreased fluid retention (p = 0.001), breast tenderness (p = 0.002), and cervical mucus (p = 0.048); there were no changes in flow or anxiety. Fluid retention in the follicular phase also significantly decreased over time (F (1.2, 14.7) = 6.7, p = 0.017). Conclusions: Pilot daily Diary data suggest women with PCOS have improved everyday experiences on cyclic progesterone therapy. Larger prospective studies with more objective outcomes and randomized controlled trials of this innovative PCOS therapy are needed.


2008 ◽  
Vol 159 (2) ◽  
pp. 121-127 ◽  
Author(s):  
Jana Vrbikova ◽  
Martin Hill ◽  
Bela Bendlova ◽  
Tereza Grimmichova ◽  
Katerina Dvorakova ◽  
...  

ObjectivePolycystic ovary syndrome (PCOS) has been linked to a high risk of type 2 diabetes mellitus. Disturbances in the secretion of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been observed in states with impaired glucose regulation. This paper considers the secretion of GIP and GLP-1 after oral glucose load in a group of lean, glucose-tolerant PCOS women in comparison with age- and body mass index (BMI)-matched healthy women.DesignCase control.MethodsPCOS (n=21, 25.8±4.1 years, BMI 21.6±1.7 kg/m2) and control healthy women (CT, n=13, 28.5±7.2 years, BMI 20.3±2.5 kg/m2) underwent oral glucose tolerance test (OGTT) with blood sampling for glucose, insulin, C-peptide, total GIP, and active GLP-1. Insulin sensitivity was determined both at fasting and during the test.StatisticsRepeated measures ANOVA.ResultsGlucose levels and insulin sensitivity did not differ between PCOS and CT. PCOS had significantly higher levels of C-peptide (P<0.05) and tended to have higher insulin levels. The levels of total GIP were significantly higher in PCOS than in CT (P<0.001). Active GLP-1 levels exhibited a significantly different time-dependent pattern in PCOS (P<0.002 for PCOS versus time interaction). GLP-1 concentrations were similar in PCOS and CT in the early phase of OGTT and then reached significantly lower levels in PCOS than in CT at 180 min (P<0.05).ConclusionsIncreased total GIP and lower late phase active GLP-1 concentrations during OGTT characterize PCOS women with higher C-peptide secretion in comparison with healthy controls, and may be the early markers of a pre-diabetic state.


Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 459
Author(s):  
Xue-Ling Xu ◽  
Shou-Long Deng ◽  
Zheng-Xing Lian ◽  
Kun Yu

Female infertility is mainly caused by ovulation disorders, which affect female reproduction and pregnancy worldwide, with polycystic ovary syndrome (PCOS) being the most prevalent of these. PCOS is a frequent endocrine disease that is associated with abnormal function of the female sex hormone estrogen and estrogen receptors (ERs). Estrogens mediate genomic effects through ERα and ERβ in target tissues. The G-protein-coupled estrogen receptor (GPER) has recently been described as mediating the non-genomic signaling of estrogen. Changes in estrogen receptor signaling pathways affect cellular activities, such as ovulation; cell cycle phase; and cell proliferation, migration, and invasion. Over the years, some selective estrogen receptor modulators (SERMs) have made substantial strides in clinical applications for subfertility with PCOS, such as tamoxifen and clomiphene, however the role of ER in PCOS still needs to be understood. This article focuses on the recent progress in PCOS caused by the abnormal expression of estrogen and ERs in the ovaries and uterus, and the clinical application of related targeted small-molecule drugs.


Sign in / Sign up

Export Citation Format

Share Document